Assessing ICU Medical (ICUI) Valuation After A Stretch Of Weak Share Price Returns

ICU Medical stock: recent performance snapshot

ICU Medical (ICUI) has drawn investor attention after a stretch of weak returns, with the share price showing declines over the past month, past 3 months, year to date, and the past year.

Against that backdrop, the company’s latest reported revenue of US$2.23b and net income of US$732,000, alongside positive annual revenue and net income growth rates, give investors concrete figures to assess the current share price.

See our latest analysis for ICU Medical.

ICU Medical’s recent 1 month share price return of a 13.15% decline and 1 year total shareholder return of a 12.27% decline point to fading momentum as the stock trades around US$125.85.

If this weaker momentum has you reassessing your exposure to healthcare, it could be a good time to broaden your search with our screener of 33 healthcare AI stocks.

With ICUI trading around US$125.85, annual revenue of US$2.23b, net income of US$732,000, and a value score of 5, should you see a mispriced healthcare stock here, or is the market already baking in future growth?

Most Popular Narrative: 31.1% Undervalued

ICU Medical’s most followed valuation view puts fair value around $182.67 per share, compared with the last close at $125.85. This frames a clear valuation gap for you to judge.

Manufacturing network consolidations, portfolio optimization, and realization of integration synergies from the Smiths Medical acquisition are driving visible improvements in gross margin. Further benefits are expected once remaining plant transitions complete over the next year, and sustained gross margin expansion supports higher profitability.

Read the complete narrative.

Curious what is backing that higher fair value? The narrative leans heavily on a sharp earnings ramp, margin rebuild, and a richer future earnings multiple. Want the full blueprint behind those assumptions?

Result: Fair Value of $182.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh risks such as tariff pressures on margins and any setbacks in integration or regulatory approvals that could undermine those upbeat assumptions.

Find out about the key risks to this ICU Medical narrative.

Next Steps

If this mix of caution and optimism around ICU Medical feels finely balanced, consider acting while the story is still evolving and weigh up the 4 key rewards and 2 important warning signs for yourself.

Looking for more investment ideas?

If ICU Medical has sharpened your focus, do not stop here. Broaden your watchlist now so you are not catching up when the next idea moves first.

• Target stability with income potential by checking out 14 dividend fortresses that could help anchor your portfolio when markets feel unpredictable.
• Spot potential mispricings early by scanning 48 high quality undervalued stocks and compare those opportunities against what you see in ICU Medical.
• Prioritise financial strength by reviewing our solid balance sheet and fundamentals stocks screener (42 results) that can help you focus on companies with room to handle setbacks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com